Icon (ICLR) Releases FY18 Earnings Guidance

Icon (NASDAQ:ICLR) updated its FY18 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $5.89-6.09 for the period, compared to the Thomson Reuters consensus estimate of $6.02. The company issued revenue guidance of $2.52-2.64 billion (taking into account ASC 606), compared to the consensus revenue estimate of $1.90 billion.

Several research analysts recently weighed in on the stock. ValuEngine upgraded shares of Icon from a hold rating to a buy rating in a research report on Tuesday. BidaskClub upgraded shares of Icon from a strong sell rating to a sell rating in a research report on Friday, February 9th. Mizuho set a $109.00 target price on shares of Icon and gave the stock a hold rating in a report on Wednesday, January 24th. SunTrust Banks reaffirmed a buy rating and set a $133.00 target price on shares of Icon in a report on Monday, January 22nd. Finally, Evercore ISI initiated coverage on shares of Icon in a report on Thursday, January 18th. They set an outperform rating and a $126.00 target price for the company. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $124.55.

Shares of Icon (NASDAQ:ICLR) opened at $110.19 on Thursday. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon has a fifty-two week low of $76.46 and a fifty-two week high of $124.48. The company has a market cap of $5,922.06, a price-to-earnings ratio of 20.99, a price-to-earnings-growth ratio of 1.54 and a beta of 0.48.

Icon (NASDAQ:ICLR) last released its earnings results on Thursday, February 15th. The medical research company reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.41 by $0.02. Icon had a net margin of 16.37% and a return on equity of 28.42%. The firm had revenue of $455.10 million during the quarter, compared to analyst estimates of $455.66 million. During the same quarter in the previous year, the business earned $1.33 EPS. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. equities analysts forecast that Icon will post 5.37 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Icon stock. Vanguard Group Inc. increased its stake in Icon Plc (NASDAQ:ICLR) by 19.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,545 shares of the medical research company’s stock after purchasing an additional 2,400 shares during the period. Vanguard Group Inc.’s holdings in Icon were worth $1,422,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 89.66% of the company’s stock.

WARNING: This piece was first published by Week Herald and is the property of of Week Herald. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://weekherald.com/2018/02/15/icon-iclr-releases-fy18-earnings-guidance.html.

Icon Company Profile

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply